2014 Half-year report on Innate Pharma’s liquidity contract with Gilbert Dupont
Innate Pharma receives $15 million milestone payment from Bristol-Myers Squibb for continued exploration of lirilumab in combination with Opdivo
Number of shares and voting rights of Innate Pharma as at January 5, 2017
Upcoming investor conferences
Innate Pharma announces its financial calendar for 2017
Innate Pharma announces key leadership and corporate governance changes to support next stage of development
Further clinical data for lirilumab and IPH4102 presented at ASH annual meeting reinforcing confidence in our programs
First clinical data for monalizumab as a single agent in cancer patients show favorable safety profile
Interim Phase 1/2 Data Show Encouraging Clinical Benefit for Lirilumab in Combination With Opdivo (Nivolumab) in Patients With Advanced Platinum Refractory Squamous Cell Carcinoma of the Head and Neck
Innate Pharma investor conference call on November 14, 2016 to discuss recent new clinical data
